REGULATED INFORMATION
The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports’. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report, the original French version will prevail.
| The BioSenic Phase 2 clinical study with arsenic trioxide in the first-line treatment of chronic Graft versus Host disease (cGvHD) has been completed and provided positive results. In 2024, the BioSenic Group expects to prioritize the use of the proceeds of anticipated future fundraising for the progression of the Phase 3 clinical trial in cGvHD. |
Mont-Saint-Guibert, Belgium, 7 September 2023, 7am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the
clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today publishes its business update for the first half, ended 30 June 2023, prepared in accordance with IFRS as adopted by the European Union, and the outlook for the remainder of the year.
"BioSenic has made the best of its efforts on restructuring and accomplishing important technical steps in implementing key features of its Arsenic salts (ATO) and its cell repair platforms after succeeding its reverse merger between Medsenic and Bone Therapeutics 10 months ago” said François Rieger, PhD, Chairman and Chief Executive Officer of BioSenic “Successfully interpreting clinical and scientific complex data – and specifically those inherited from the former Bone Therapeutics – gives us now the essential basic elements to develop our activities on licensing opportunities and further Phase 2/3 clinical trials. Our immediate leading project is a Phase 3 confirmatory trial on the efficacy of an oral formulation of arsenic trioxide on chronic Graft-versus-Host Disease, an autoimmune rare condition following allogeneic hematopoietic cells used for treating several types of leukaemia. We now expect a productive end of 2023 for further developing the best values of BioSenic."
Operational and Corporate highlights
- In January 2023, BioSenic strengthened its scientific team with the appointment of Dr. Carole Nicco, as Chief Scientific Officer (CSO).
- In January 2023, BioSenic appointed Yves Sagot as a member of the Board of Directors and Independent Director.
- In March 2023, BioSenic re-evaluated the results of its Phase 3 trial of its enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA). The Company indeed announced that it has used the statistical analysis capabilities of Artialis to study the results of the Phase 3 JTA-004 trial in the subset of patients with the most painful and inflammatory form of knee osteoarthritis (OA). This allows BioSenic to distinguish a group of patients, representing about one third of the total patients, who show a pain-relieving effect of JTA-004 not only superior to placebo but also to the active comparator. This new post-hoc analysis changes the therapeutic profile of the molecule and potentially allows for the possibility of stratifying patients for a new, optimized Phase 3 clinical study.
- In March 2023, BioSenic published new data on the mechanism of action of arsenic trioxide (ATO) to prevent autoimmune diseases has now been published in a peer-reviewed paper (Frontiers in Immunology). This new data shows that combination of ATO with copper salts can allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacy. This new formulation data has been completed following pre-clinical activities and does not constitute data validated through clinical trial.
- In April 2023, BioSenic appointed Lieven Huysse, MD, as permanent Chief Medical Officer (CMO).
- In April 2023, BioSenic received European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases. The patent covers the therapeutic use of a new composite formulation of anti-inflammatory compounds with unique advantages. This new formulation lowers the dosage of arsenic trioxide by combining it with copper salts to maintain therapeutic efficacy, with the potential of administration through multiple routes, including intravenous, oral, and other novel routes of administration.
- In May 2023, BioSenic identified key biomarkers for cGvHD and submitted patent to EPO. The technology covered by the patent applies to a method and kit for diagnosing and monitoring cGvHD in an individual who has undergone an allogeneic hematopoietic stem cell transplantation. The patent describes biomarkers to be used to determine if the condition of a patient worsens or improves following standard or new treatments for cGvHD. This international patent could allow the development of an industrial biomarker analysis kit which could generate a turnover of 30 to 40 million euros globally.
- In June 2023, BioSenic put Phase 2b ALLOB trial on hold. This decision follows negative results obtained for the primary endpoint in the exploratory Phase 2b trial (ALLOB 2b), which focused on safety and treatment timing efficacy.
- In August 2023, BioSenic received a Chinese patent protecting the combined use of metal ions and arsenic salts. This patent (ZL202080040613.1) covers the use of its ATO platform in combination with metal ions like copper, which has the potential to improve the treatment of autoimmune diseases.
Financial highlights
- In February 2023, BioSenic received EUR 1 million from Pregene in accordance with terminated license agreement.
- In June 2023, BioSenic has obtained an official appointment of Yves Brulard to reach a negotiated agreement with certain main creditors to preserve the value of BioSenic for the benefit of all stakeholders.
- In June 2023, BioSenic entered into an agreement with the ABO Securities subsidiary, Global Tech Opportunities 15, to secure short term financing based on the existing convertible bond program. Subject to the terms and conditions of the agreement, BioSenic shall be entitled to draw down three tranches of each EUR 0.3 million in June, July, and August under the existing convertible bond program, for an aggregate principal amount of EUR 0.9 million.
- In July 2023, BioSenic has achieved a standstill agreement from the main historical creditors for a period of 3 to 4 months. Given this agreement with the main creditors and the one obtained on 30 June 2023 with Global Tech Opportunities 15 to secure short-term financing based on the existing convertible bond program, BioSenic anticipates having sufficient cash to carry out its business objectives until October 2023.
- During the first six months of 2023, total operating income amounted to EUR 0.37 million, a slight increase compared to the same period in 2022 (EUR 0.13 million).
- Operating loss for the period amounted to EUR 3.90 million, compared to EUR 3.96 million in H1 2022.
- BioSenic ended the first six months of 2023 with EUR 0.52 million in cash and cash equivalents. Net cash used for the period amounted to EUR 1.33 million, compared to EUR 0.39 million over the same period of 2022.
Outlook for the remainder of 2023 and 2024
- In March 2023, BioSenic has obtained new statistical analysis results from the JTA-004 Phase 3 clinical trial data. BioSenic, which does not intend to allocate R&D resources to support the clinical development of JTA-004, is seeking to collaborate with existing and potential partners to explore options for the future development of JTA-004 based on this new post-hoc analysis. Following disappointing Phase 3 clinical results, Biosenic terminated the agreement with the Walloon Region and Mr Bastianelli in 2022. The agreement with the Walloon Region has since been resumed, but there is still no agreement with Mr Enrico Bastianelli, which could give rise to co-ownership problems.
- The Medsenic Phase 2 clinical study with arsenic trioxide in the first-line treatment of cGvHD has been completed and provided positive results. A Phase 3 study with oral arsenic trioxide in the first-line treatment of cGvHD, for which Medsenic received positive pre-IND response from the FDA, is currently anticipated to start in 2024. A Phase 2a clinical trial for systemic lupus erythematosus ("SLE") had previously established safety for the patient and efficacy on the course of the autoimmune disease. Positive preclinical work gives good grounds for a Phase 2 clinical trial on systemic sclerosis ("SSc"). Phase 2b clinical trials for SLE and SSc are in the planning stage with the protocols for both studies being ready.
- BioSenic is currently preparing a fundraising to be organized in Q3/Q4 2023. BioSenic Group expects for 2024 to use the proceeds of anticipated future fundraisings in priority for progressing the Phase 3 clinical trial in cGvHD. As a result, it will only be possible to start the SLE and SSc Phase 2b clinical trials if the BioSenic Group succeeds in concluding a strong partnership with a biopharmaceutical company or if it manages to successfully out-license some of its technology. The start of SLE and SSc Phase 2 clinical trials is therefore not envisioned before 2024.
Unaudited Interim Condensed Consolidated Statement of Comprehensive Income
| (in thousands of euros) | For the six-months period ended | |
| 30/06/2023 | 30/06/2022 | |
| Revenues | 0 | 0 |
| Other operating income | 365 | 125 |
| Total revenues and operating income | 365 | 125 |
| Research and development expenses | (2,452) | (267) |
| General and administrative expenses | (1,813) | (336) |
| Other operating expenses | (1) | 0 |
| Operating profit/(loss) | (3,900) | (478) |
| Financial Income | 35 | 0 |
| Interest income | 30 | 0 |
| Impairment expenses | (16,094) | 0 |
| Financial expenses | (1,136) | (49) |
| Exchange gains/(losses) | 1 | 0 |
| Result Profit/(loss) before taxes | (21,063) | (527) |
| Income taxes | (24) | - |
| Result Profit/(loss) for the Period | (21,087) | (527) |
| Thereof attributable to: | ||
| Owners of the Company | (20,843) | (527) |
| Non-controlling interests | (244) | 0 |
| Other comprehensive income | 0 | 0 |
| TOTAL COMPREHENSIVE INCOME/(LOSS) OF THE PERIOD | (21,087) | (527) |
| Thereof attributable to: | ||
| Owners of the Company | (20,843) | (527) |
| Non-controlling interests | (244) | 0 |
| Basic and diluted loss per share (in euros) | (0,17) | (7,49) |
Unaudited Interim Condensed Consolidated Statement of Financial Position
| Consolidated Assets IFRS per: (in thousands of euros) | 30/06/2023 | 31/12/2022 | |
| Non-current assets Goodwill | 7,848 0 | 24,698 1,802 | |
| Intangible assets | 2,995 | 17,293 | |
| Property, plant and equipment | 786 | 1,419 | |
| Finance lease receivable | 469 | 0 | |
| Investments in associates | 12 | 12 | |
| Other non-current assets | 135 | 136 | |
| R&D Tax Credits | 3,452 | 4,036 | |
| Current assets | 2,544 | 4,626 | |
| Trade and other receivables | 1,676 | 2,490 | |
| Other current assets | 214 | 290 | |
| Finance lease receivable | 135 | 0 | |
| Cash and cash equivalents | 519 | 1,846 | |
| TOTAL ASSETS | 10,392 | 29,324 |
| Consolidated Equity & Liabilities IFRS per: (in thousands of euros) | 30/06/2023 | 31/12/2022 | |
| Equity attributable to owners of the parent | (16,882) | 3,526 | |
| Share capital | 5,224 | 4,774 | |
| Share premium | 4,594 | 4,517 | |
| Accumulated losses and other reserves | (26,652) | (5,723) | |
| Other reserves | (48) | (42) | |
| Equity attributable to owners of the parent | |||
| Non-controlling interests | (646) | (402) | |
| Total Equity | (17,528) | 3,124 | |
| Non-current liabilities | 15,764 | 15,847 | |
| Interest bearing borrowings | 15,696 | 15,779 | |
| Other non-current liabilities | 68 | 68 | |
| Current liabilities | 12,156 | 10,353 | |
| Interest bearing borrowings | 9,339 | 8,013 | |
| Trade and other payables | 2,728 | 2,236 | |
| Other current liabilities | 89 | 104 | |
| Total liabilities | 27,920 | 26,200 | |
| TOTAL EQUITY AND LIABILITIES | 10,392 | 29,324 |
Unaudited Interim Condensed Consolidated Statement of Cash Flows
| Consolidated Statement of Cash Flows (in thousands of euros) | For the six-month period ended 30 June | |
| 2023 | 2022 | |
| CASH FLOW FROM OPERATING ACTIVITIES | ||
| Operating profit/(loss) | (3,900) | (478) |
| Adjustments for: | ||
| Depreciation and Amortisation | 101 | 5 |
| Grants income related to tax credit | (115) | 0 |
| Grants income related to withholding tax | (47) | |
| Other | (68) | 0 |
| Movements in working capital: | ||
| (Increase)/Decrease in Trade and other receivables (excluding government grants) | (34) | 14 |
| Increase/(Decrease) in Trade and other Payables | 492 | 22 |
| Cash used by operations | (3,570) | (438) |
| Cash received from license agreement | 940 | 0 |
| Cash received from grants related to tax credit | 700 | 187 |
| Net cash used in operating activities | (1,930) | (251) |
| CASH FLOW FROM INVESTING ACTIVITIES | ||
| Disposal of intangible assets | 17 | 0 |
| Disposal of property, plant and equipment | 3 | 0 |
| Purchases of property, plant and equipment | (12) | 0 |
| Purchases of intangible assets | (1) | 0 |
| Net cash generated from investing activities | 7 | 0 |
| CASH FLOW FROM FINANCING ACTIVITIES | ||
| Repayment of borrowings | (150) | (45) |
| Proceeds from convertible borrowings | 550 | 0 |
| Repayment of lease liabilities | (84) | (2) |
| Repayment of other financial liabilities | (75) | (75) |
| Interests paid | (13) | (16) |
| Transaction costs | (81) | |
| Proceeds from issue of equity instruments | 450 | 0 |
| Net cash generated from financing activities | 596 | (137) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (1,327) | (388) |
| CASH AND CASH EQUIVALENTS at beginning of the period | 1,846 | 759 |
| CASH AND CASH EQUIVALENTS at end of the period | 519 | 371 |
Unaudited Interim Condensed Consolidated Statement of Changes in Shareholders' Equity
| Attributable to owners of the parent | Non-controlling interests | TOTAL EQUITY | ||||
| (in thousands of euros) | Share capital | Share premium | Accumulated Losses & other reserves | Other elements of comprehensive income | ||
| BALANCE AT 1 JANUARY 2022 | 664 | 3,969 | (7,298) | (5) | 0 | (2,670) |
| Total comprehensive income of the period | 0 | 0 | (527) | 0 | 0 | (527) |
| Issue of share capital | 74 | 3,837 | 0 | 0 | 0 | 3,911 |
| BALANCE AT 30 JUNE 2022 | 738 | 7,806 | (7,825) | (5) | 0 | 714 |
| BALANCE AT 1 JANUARY 2023 | 4,774 | 4,517 | (5,723) | (42) | (402) | 3,124 |
| Total comprehensive income of the period | 0 | 0 | (20,843) | 0 | (244) | (21,087) |
| Issue of share capital | 450 | 158 | 0 | 0 | 0 | 609 |
| Transaction costs for equity issue | 0 | (81) | 0 | 0 | 0 | (81) |
| Other | 0 | 0 | (85) | (6) | 0 | (91) |
| BALANCE AT 30 JUNE 2023 | 5,224 | 4,594 | (26,652) | (48) | (646) | (17,528) |
About BioSenic
The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports’. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report, the original French version will prevail.
BioSenic reports half year 2023 results
| The BioSenic Phase 2 clinical study with arsenic trioxide in the first-line treatment of chronic Graft versus Host disease (cGvHD) has been completed and provided positive results. In 2024, the BioSenic Group expects to prioritize the use of the proceeds of anticipated future fundraising for the progression of the Phase 3 clinical trial in cGvHD. |
Mont-Saint-Guibert, Belgium, 7 September 2023, 7am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the
clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today publishes its business update for the first half, ended 30 June 2023, prepared in accordance with IFRS as adopted by the European Union, and the outlook for the remainder of the year.
"BioSenic has made the best of its efforts on restructuring and accomplishing important technical steps in implementing key features of its Arsenic salts (ATO) and its cell repair platforms after succeeding its reverse merger between Medsenic and Bone Therapeutics 10 months ago” said François Rieger, PhD, Chairman and Chief Executive Officer of BioSenic “Successfully interpreting clinical and scientific complex data – and specifically those inherited from the former Bone Therapeutics – gives us now the essential basic elements to develop our activities on licensing opportunities and further Phase 2/3 clinical trials. Our immediate leading project is a Phase 3 confirmatory trial on the efficacy of an oral formulation of arsenic trioxide on chronic Graft-versus-Host Disease, an autoimmune rare condition following allogeneic hematopoietic cells used for treating several types of leukaemia. We now expect a productive end of 2023 for further developing the best values of BioSenic."
Operational and Corporate highlights
- In January 2023, BioSenic strengthened its scientific team with the appointment of Dr. Carole Nicco, as Chief Scientific Officer (CSO).
- In January 2023, BioSenic appointed Yves Sagot as a member of the Board of Directors and Independent Director.
- In March 2023, BioSenic re-evaluated the results of its Phase 3 trial of its enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA). The Company indeed announced that it has used the statistical analysis capabilities of Artialis to study the results of the Phase 3 JTA-004 trial in the subset of patients with the most painful and inflammatory form of knee osteoarthritis (OA). This allows BioSenic to distinguish a group of patients, representing about one third of the total patients, who show a pain-relieving effect of JTA-004 not only superior to placebo but also to the active comparator. This new post-hoc analysis changes the therapeutic profile of the molecule and potentially allows for the possibility of stratifying patients for a new, optimized Phase 3 clinical study.
- In March 2023, BioSenic published new data on the mechanism of action of arsenic trioxide (ATO) to prevent autoimmune diseases has now been published in a peer-reviewed paper (Frontiers in Immunology). This new data shows that combination of ATO with copper salts can allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacy. This new formulation data has been completed following pre-clinical activities and does not constitute data validated through clinical trial.
- In April 2023, BioSenic appointed Lieven Huysse, MD, as permanent Chief Medical Officer (CMO).
- In April 2023, BioSenic received European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases. The patent covers the therapeutic use of a new composite formulation of anti-inflammatory compounds with unique advantages. This new formulation lowers the dosage of arsenic trioxide by combining it with copper salts to maintain therapeutic efficacy, with the potential of administration through multiple routes, including intravenous, oral, and other novel routes of administration.
- In May 2023, BioSenic identified key biomarkers for cGvHD and submitted patent to EPO. The technology covered by the patent applies to a method and kit for diagnosing and monitoring cGvHD in an individual who has undergone an allogeneic hematopoietic stem cell transplantation. The patent describes biomarkers to be used to determine if the condition of a patient worsens or improves following standard or new treatments for cGvHD. This international patent could allow the development of an industrial biomarker analysis kit which could generate a turnover of 30 to 40 million euros globally.
- In June 2023, BioSenic put Phase 2b ALLOB trial on hold. This decision follows negative results obtained for the primary endpoint in the exploratory Phase 2b trial (ALLOB 2b), which focused on safety and treatment timing efficacy.
- In August 2023, BioSenic received a Chinese patent protecting the combined use of metal ions and arsenic salts. This patent (ZL202080040613.1) covers the use of its ATO platform in combination with metal ions like copper, which has the potential to improve the treatment of autoimmune diseases.
Financial highlights
- In February 2023, BioSenic received EUR 1 million from Pregene in accordance with terminated license agreement.
- In June 2023, BioSenic has obtained an official appointment of Yves Brulard to reach a negotiated agreement with certain main creditors to preserve the value of BioSenic for the benefit of all stakeholders.
- In June 2023, BioSenic entered into an agreement with the ABO Securities subsidiary, Global Tech Opportunities 15, to secure short term financing based on the existing convertible bond program. Subject to the terms and conditions of the agreement, BioSenic shall be entitled to draw down three tranches of each EUR 0.3 million in June, July, and August under the existing convertible bond program, for an aggregate principal amount of EUR 0.9 million.
- In July 2023, BioSenic has achieved a standstill agreement from the main historical creditors for a period of 3 to 4 months. Given this agreement with the main creditors and the one obtained on 30 June 2023 with Global Tech Opportunities 15 to secure short-term financing based on the existing convertible bond program, BioSenic anticipates having sufficient cash to carry out its business objectives until October 2023.
- During the first six months of 2023, total operating income amounted to EUR 0.37 million, a slight increase compared to the same period in 2022 (EUR 0.13 million).
- Operating loss for the period amounted to EUR 3.90 million, compared to EUR 3.96 million in H1 2022.
- BioSenic ended the first six months of 2023 with EUR 0.52 million in cash and cash equivalents. Net cash used for the period amounted to EUR 1.33 million, compared to EUR 0.39 million over the same period of 2022.
Outlook for the remainder of 2023 and 2024
- In March 2023, BioSenic has obtained new statistical analysis results from the JTA-004 Phase 3 clinical trial data. BioSenic, which does not intend to allocate R&D resources to support the clinical development of JTA-004, is seeking to collaborate with existing and potential partners to explore options for the future development of JTA-004 based on this new post-hoc analysis. Following disappointing Phase 3 clinical results, Biosenic terminated the agreement with the Walloon Region and Mr Bastianelli in 2022. The agreement with the Walloon Region has since been resumed, but there is still no agreement with Mr Enrico Bastianelli, which could give rise to co-ownership problems.
- The Medsenic Phase 2 clinical study with arsenic trioxide in the first-line treatment of cGvHD has been completed and provided positive results. A Phase 3 study with oral arsenic trioxide in the first-line treatment of cGvHD, for which Medsenic received positive pre-IND response from the FDA, is currently anticipated to start in 2024. A Phase 2a clinical trial for systemic lupus erythematosus ("SLE") had previously established safety for the patient and efficacy on the course of the autoimmune disease. Positive preclinical work gives good grounds for a Phase 2 clinical trial on systemic sclerosis ("SSc"). Phase 2b clinical trials for SLE and SSc are in the planning stage with the protocols for both studies being ready.
- BioSenic is currently preparing a fundraising to be organized in Q3/Q4 2023. BioSenic Group expects for 2024 to use the proceeds of anticipated future fundraisings in priority for progressing the Phase 3 clinical trial in cGvHD. As a result, it will only be possible to start the SLE and SSc Phase 2b clinical trials if the BioSenic Group succeeds in concluding a strong partnership with a biopharmaceutical company or if it manages to successfully out-license some of its technology. The start of SLE and SSc Phase 2 clinical trials is therefore not envisioned before 2024.
Unaudited Interim Condensed Consolidated Statement of Comprehensive Income
| (in thousands of euros) | For the six-months period ended | |
| 30/06/2023 | 30/06/2022 | |
| Revenues | 0 | 0 |
| Other operating income | 365 | 125 |
| Total revenues and operating income | 365 | 125 |
| Research and development expenses | (2,452) | (267) |
| General and administrative expenses | (1,813) | (336) |
| Other operating expenses | (1) | 0 |
| Operating profit/(loss) | (3,900) | (478) |
| Financial Income | 35 | 0 |
| Interest income | 30 | 0 |
| Impairment expenses | (16,094) | 0 |
| Financial expenses | (1,136) | (49) |
| Exchange gains/(losses) | 1 | 0 |
| Result Profit/(loss) before taxes | (21,063) | (527) |
| Income taxes | (24) | - |
| Result Profit/(loss) for the Period | (21,087) | (527) |
| Thereof attributable to: | ||
| Owners of the Company | (20,843) | (527) |
| Non-controlling interests | (244) | 0 |
| Other comprehensive income | 0 | 0 |
| TOTAL COMPREHENSIVE INCOME/(LOSS) OF THE PERIOD | (21,087) | (527) |
| Thereof attributable to: | ||
| Owners of the Company | (20,843) | (527) |
| Non-controlling interests | (244) | 0 |
| Basic and diluted loss per share (in euros) | (0,17) | (7,49) |
Unaudited Interim Condensed Consolidated Statement of Financial Position
| Consolidated Assets IFRS per: (in thousands of euros) | 30/06/2023 | 31/12/2022 |
| Non-current assets Goodwill | 7,848 0 | 24,698 1,802 |
| Intangible assets | 2,995 | 17,293 |
| Property, plant and equipment | 786 | 1,419 |
| Finance lease receivable | 469 | 0 |
| Investments in associates | 12 | 12 |
| Other non-current assets | 135 | 136 |
| R&D Tax Credits | 3,452 | 4,036 |
| Current assets | 2,544 | 4,626 |
| Trade and other receivables | 1,676 | 2,490 |
| Other current assets | 214 | 290 |
| Finance lease receivable | 135 | 0 |
| Cash and cash equivalents | 519 | 1,846 |
| TOTAL ASSETS | 10,392 | 29,324 |
| Consolidated Equity & Liabilities IFRS per: (in thousands of euros) | 30/06/2023 | 31/12/2022 |
| Equity attributable to owners of the parent | (16,882) | 3,526 |
| Share capital | 5,224 | 4,774 |
| Share premium | 4,594 | 4,517 |
| Accumulated losses and other reserves | (26,652) | (5,723) |
| Other reserves | (48) | (42) |
| Equity attributable to owners of the parent | ||
| Non-controlling interests | (646) | (402) |
| Total Equity | (17,528) | 3,124 |
| Non-current liabilities | 15,764 | 15,847 |
| Interest bearing borrowings | 15,696 | 15,779 |
| Other non-current liabilities | 68 | 68 |
| Current liabilities | 12,156 | 10,353 |
| Interest bearing borrowings | 9,339 | 8,013 |
| Trade and other payables | 2,728 | 2,236 |
| Other current liabilities | 89 | 104 |
| Total liabilities | 27,920 | 26,200 |
| TOTAL EQUITY AND LIABILITIES | 10,392 | 29,324 |
Unaudited Interim Condensed Consolidated Statement of Cash Flows
| Consolidated Statement of Cash Flows (in thousands of euros) | For the six-month period ended 30 June | |
| 2023 | 2022 | |
| CASH FLOW FROM OPERATING ACTIVITIES | ||
| Operating profit/(loss) | (3,900) | (478) |
| Adjustments for: | ||
| Depreciation and Amortisation | 101 | 5 |
| Grants income related to tax credit | (115) | 0 |
| Grants income related to withholding tax | (47) | |
| Other | (68) | 0 |
| Movements in working capital: | ||
| (Increase)/Decrease in Trade and other receivables (excluding government grants) | (34) | 14 |
| Increase/(Decrease) in Trade and other Payables | 492 | 22 |
| Cash used by operations | (3,570) | (438) |
| Cash received from license agreement | 940 | 0 |
| Cash received from grants related to tax credit | 700 | 187 |
| Net cash used in operating activities | (1,930) | (251) |
| CASH FLOW FROM INVESTING ACTIVITIES | ||
| Disposal of intangible assets | 17 | 0 |
| Disposal of property, plant and equipment | 3 | 0 |
| Purchases of property, plant and equipment | (12) | 0 |
| Purchases of intangible assets | (1) | 0 |
| Net cash generated from investing activities | 7 | 0 |
| CASH FLOW FROM FINANCING ACTIVITIES | ||
| Repayment of borrowings | (150) | (45) |
| Proceeds from convertible borrowings | 550 | 0 |
| Repayment of lease liabilities | (84) | (2) |
| Repayment of other financial liabilities | (75) | (75) |
| Interests paid | (13) | (16) |
| Transaction costs | (81) | |
| Proceeds from issue of equity instruments | 450 | 0 |
| Net cash generated from financing activities | 596 | (137) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (1,327) | (388) |
| CASH AND CASH EQUIVALENTS at beginning of the period | 1,846 | 759 |
| CASH AND CASH EQUIVALENTS at end of the period | 519 | 371 |
Unaudited Interim Condensed Consolidated Statement of Changes in Shareholders' Equity
| Attributable to owners of the parent | Non-controlling interests | TOTAL EQUITY | ||||
| (in thousands of euros) | Share capital | Share premium | Accumulated Losses & other reserves | Other elements of comprehensive income | ||
| BALANCE AT 1 JANUARY 2022 | 664 | 3,969 | (7,298) | (5) | 0 | (2,670) |
| Total comprehensive income of the period | 0 | 0 | (527) | 0 | 0 | (527) |
| Issue of share capital | 74 | 3,837 | 0 | 0 | 0 | 3,911 |
| BALANCE AT 30 JUNE 2022 | 738 | 7,806 | (7,825) | (5) | 0 | 714 |
| BALANCE AT 1 JANUARY 2023 | 4,774 | 4,517 | (5,723) | (42) | (402) | 3,124 |
| Total comprehensive income of the period | 0 | 0 | (20,843) | 0 | (244) | (21,087) |
| Issue of share capital | 450 | 158 | 0 | 0 | 0 | 609 |
| Transaction costs for equity issue | 0 | (81) | 0 | 0 | 0 | (81) |
| Other | 0 | 0 | (85) | (6) | 0 | (91) |
| BALANCE AT 30 JUNE 2023 | 5,224 | 4,594 | (26,652) | (48) | (646) | (17,528) |
About BioSenic
BioSenic is a leading biotech company specializing in the development of clinical assets issued from: (i) the arsenic trioxide (ATO) platform (with key target indications including Graft-versus-Host Disease (GvHD), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) and (ii), the development of innovative products to meet unmet needs in orthopedics.
Following a reverse merger in October 2022, BioSenic combined a strategic positionings and strengths to use, separately and combined, an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO) with its innovative cell therapy platform and strong IP for tissue repair protection.
BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at http://www.biosenic.com.
About BioSenic technology platforms
BioSenic’s technology is based on two main platforms:
1) The ATO platform, which has been successfully developed, has immunomodulatory properties with fundamental effects on the activated cells of the immune system. The first effect is the increase of the cell oxidative stress in activated B, T and other cells of the innate/adaptative immune system to the point they will enter a cell death program (apoptosis) and be eliminated. The second effect is potent immunomodulatory properties on several cytokines involved in inflammatory or autoimmune cell pathways, with return to homeostasis. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT). cGvHD is primarily mediated by the transplanted immune cells that can lead to severe multiorgan damage. BioSenic has been successful in a Phase 2 trial with its intravenous formulation, which has orphan drug designation status by FDA and EMA. The Company is heading towards an international Phase 3 confirmatory study, with its new, IP-protected, OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE), using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin, mucosae and the gastrointestinal tract) in an early Phase 2a study. Systemic sclerosis is also part of the clinical pipeline of BioSenic. This serious chronic disease badly affects skin, lungs or vascularization, and has no actual current effective treatment. Preclinical studies on pertinent animal models are positive, giving good grounds to launch a Phase 2 clinical protocol.
2) The allogeneic cell and gene therapy platform developed by BioSenic, with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs), which can be stored at the point of use in hospitals. ALLOB represents a unique and proprietary approach to organ repair and specifically to bone regeneration, by turning undifferentiated stromal cells from healthy donors into bone-forming cells on the site of injury. ALLOB has recently been evaluated in a randomized, double-blind, placebo-controlled Phase 2b study in patients with high-risk tibial fractures, using its optimized production process, after a successful first safety and efficacy study (Phase 1/2a) on fractured long bones, with late-delayed union. However, in June 2023, BioSenic decided to suspend its interventional trial on fracture healing using ALLOB, following negative results obtained for the primary endpoint in this exploratory Phase 2b clinical trial, interpreted as a failure of a too early cell injection, just after fracture. BioSenic is now focusing on determining the best time to optimise the efficacy of ALLOB (choice between early or late treatment).
Note: Biosenic has reevaluated a previous important and years-long clinical development program. In March 2023, after the clinical identification of distinct OA subtypes, BioSenic delivered a new post-hoc analysis of its Phase 3 JTA-004 trial on knee OA, demonstrating positive action on the most severely affected patient subpopulation. This new post-hoc analysis drastically changes the therapeutic profile of the combined components and allows for better patient targeting in future clinical developments. This leads to a next generation of JTA, off-the-shelf enhanced viscosupplement to treat knee osteoarthritis (OA), made of a unique combination of mammalian plasma proteins, derivatives of hyaluronic acid (a natural component of synovial fluid in the knee) and a third active component. JTA or some derivatives are intended to provide effective lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic (OA) pain and inflammation.
The company, will nevertheless focus its present R&D and clinical activities on a selective, accelerated development of its autoimmune (ATO/OATO) platform.
For further information, please contact:
BioSenic SA
François Rieger, PhD, Chief Executive Officer
Tel: +33 (0)671 73 31 59
investorrelations@biosenic.com
International Media Enquiries:
IB Communications
Neil Hunter / Michelle Boxall
Tel: +44 (0)20 8943 4685
neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:
Seitosei Actifin
Ghislaine Gasparetto
Tel: +33 (0)1 56 88 11 22
ggasparetto@actifin.fr
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
BioSenic is a leading biotech company specializing in the development of clinical assets issued from: (i) the arsenic trioxide (ATO) platform (with key target indications including Graft-versus-Host Disease (GvHD), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) and (ii), the development of innovative products to meet unmet needs in orthopedics.
Following a reverse merger in October 2022, BioSenic combined a strategic positionings and strengths to use, separately and combined, an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO) with its innovative cell therapy platform and strong IP for tissue repair protection.
BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at http://www.biosenic.com.
About BioSenic technology platforms
BioSenic’s technology is based on two main platforms:
- The ATO platform, which has been successfully developed, has immunomodulatory properties with fundamental effects on the activated cells of the immune system. The first effect is the increase of the cell oxidative stress in activated B, T and other cells of the innate/adaptative immune system to the point they will enter a cell death program (apoptosis) and be eliminated. The second effect is potent immunomodulatory properties on several cytokines involved in inflammatory or autoimmune cell pathways, with return to homeostasis. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT). cGvHD is primarily mediated by the transplanted immune cells that can lead to severe multiorgan damage. BioSenic has been successful in a Phase 2 trial with its intravenous formulation, which has orphan drug designation status by FDA and EMA. The Company is heading towards an international Phase 3 confirmatory study, with its new, IP-protected, OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE), using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin, mucosae and the gastrointestinal tract) in an early Phase 2a study. Systemic sclerosis is also part of the clinical pipeline of BioSenic. This serious chronic disease badly affects skin, lungs or vascularization, and has no actual current effective treatment. Preclinical studies on pertinent animal models are positive, giving good grounds to launch a Phase 2 clinical protocol.
- The allogeneic cell and gene therapy platform developed by BioSenic, with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs), which can be stored at the point of use in hospitals. ALLOB represents a unique and proprietary approach to organ repair and specifically to bone regeneration, by turning undifferentiated stromal cells from healthy donors into bone-forming cells on the site of injury. ALLOB has recently been evaluated in a randomized, double-blind, placebo-controlled Phase 2b study in patients with high-risk tibial fractures, using its optimized production process, after a successful first safety and efficacy study (Phase 1/2a) on fractured long bones, with late-delayed union. However, in June 2023, BioSenic decided to suspend its interventional trial on fracture healing using ALLOB, following negative results obtained for the primary endpoint in this exploratory Phase 2b clinical trial, interpreted as a failure of a too early cell injection, just after fracture. BioSenic is now focusing on determining the best time to optimise the efficacy of ALLOB (choice between early or late treatment).
Note: Biosenic has reevaluated a previous important and years-long clinical development program. In March 2023, after the clinical identification of distinct OA subtypes, BioSenic delivered a new post-hoc analysis of its Phase 3 JTA-004 trial on knee OA, demonstrating positive action on the most severely affected patient subpopulation. This new post-hoc analysis drastically changes the therapeutic profile of the combined components and allows for better patient targeting in future clinical developments. This leads to a next generation of JTA, off-the-shelf enhanced viscosupplement to treat knee osteoarthritis (OA), made of a unique combination of mammalian plasma proteins, derivatives of hyaluronic acid (a natural component of synovial fluid in the knee) and a third active component. JTA or some derivatives are intended to provide effective lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic (OA) pain and inflammation.
The company, will nevertheless focus its present R&D and clinical activities on a selective, accelerated development of its autoimmune (ATO/OATO) platform.
For further information, please contact:
BioSenic SA
François Rieger, PhD, Chief Executive Officer
Tel: +33 (0)671 73 31 59
investorrelations@biosenic.com
International Media Enquiries:
IB Communications
Neil Hunter / Michelle Boxall
Tel: +44 (0)20 8943 4685
neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:
Seitosei Actifin
Ghislaine Gasparetto
Tel: +33 (0)1 56 88 11 22
ggasparetto@actifin.fr
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
